Title: Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for
patients with T4b esophageal squamous cell carcinoma
Version: 1 Date: 27 Nov 2023
Reviewer's report:
-"Efficacy for the primary lesion was evaluated by our original formula for the tumor reduction
rate."  How was this developed and validated?
-Why are these considered induction cases?  A better title might be 'Treatment of T4b ESCC
with pembrolizumab plus cisplatin and 5-fluorouracil ."
-Induction is not indicated for patients that have M1 disease (5 have this).
-You could also include the number of cycles received in the  table 2.
-I think you are making 2 points with this:  1) chemo/pembro better tolerated the DCFJ and 2)
chemo/pembro can be effective.
-There are too few cases to comment on the impact of cps score.
-Fig 1 and discussion of hyperprogression belongs in the results section.
Title: Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for
patients with T4b esophageal squamous cell carcinoma
Version: 1 Date: 27 Nov 2023
Reviewer's report:
-"Efficacy for the primary lesion was evaluated by our original formula for the tumor reduction
rate."  How was this developed and validated?
-Why are these considered induction cases?  A better title might be 'Treatment of T4b ESCC
with pembrolizumab plus cisplatin and 5-fluorouracil ."
-Induction is not indicated for patients that have M1 disease (5 have this).
-You could also include the number of cycles received in the  table 2.
-I think you are making 2 points with this:  1) chemo/pembro better tolerated the DCFJ and 2)
chemo/pembro can be effective.
-There are too few cases to comment on the impact of cps score.
-Fig 1 and discussion of hyperprogression belongs in the results section.
Please review this paper.
user
Title: Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for
patients with T4b esophageal squamous cell carcinoma
Version: 1 Date: 27 Nov 2023
Reviewer's report:
-"Efficacy for the primary lesion was evaluated by our original formula for the tumor reduction
rate."  How was this developed and validated?
-Why are these considered induction cases?  A better title might be 'Treatment of T4b ESCC
with pembrolizumab plus cisplatin and 5-fluorouracil ."
-Induction is not indicated for patients that have M1 disease (5 have this).
-You could also include the number of cycles received in the  table 2.
-I think you are making 2 points with this:  1) chemo/pembro better tolerated the DCFJ and 2)
chemo/pembro can be effective.
-There are too few cases to comment on the impact of cps score.
-Fig 1 and discussion of hyperprogression belongs in the results section.
assistant